Autoimmune Diseases  >>  Hizentra (human immune globulin subcutaneous 20%)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
SIMM, NCT01828294: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis

Terminated
1
4
US
Subcutaneous immunoglobulins, Hizentra
St. Louis University, CSL Behring
Myasthenia Gravis
12/17
12/17

Download Options